arrow
T

Tiziana Ottone

University of Rome Tor Vergata
H指数:30
被引数:2,758

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic Impact of FLT3 ‐ ITD Microclones in AML : An EHA AML ‐Specialized Working Group Study

FLT3-ITD微小克隆在AML中的预后影响:EHA AML专业化工作组研究

2026-11-010
PRE
Characterization of FLT3-ITD-mutated leukemic stem cells: functional and clinical insights

FLT3-ITD突变白血病干细胞的表征:功能与临床见解

2026-09-280
OAAI
Transcriptomic profile and endothelial changes during differentiation syndrome in acute promyelocytic leukemia

急性早幼粒细胞白血病分化综合征期间的转录组谱和内皮变化

2026-09-020
OAAI
APL-like subset within NPM1-mutated AML: A distinct immunophenotype correlating with early vascular complications

NPM1突变AML中APL样亚群:一种与早期血管并发症相关的独特免疫表型

2026-04-160
OA
PML::RARα+ myeloid cells display metabolic alterations that can be targeted to treat resistant/relapse acute promyelocytic leukemias

PML::RARα+髓系细胞表现出可被靶向以治疗耐药/复发性急性早幼粒细胞白血病的代谢改变。

Leukemia
IF13.4
2025-09-100
OAAI
A fatal case of peritonitis due to colonic localization of acute myeloid leukemia
2025-01-070
PRE
Retinoic acid and proteotoxic stress induce AML cell death overcoming stromal cell protection
2023-08-313
OAAI
MCL1 regulates AML cells metabolism via direct interaction with HK2. Metabolic signature at onset predicts overall survival in AMLs' patients
LEUKEMIA
IF13.4
2023-06-228
OA
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial

在CALGB 10603/批准试验中治疗的FLT3-mutated急性髓系白血病 (AML) 患者的基因组景观

LEUKEMIA
IF13.4
2022-08-0325
OAAI
Vitamin C Deficiency in Patients With Acute Myeloid Leukemia
2022-06-279
OAAI
CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AML
LEUKEMIA
IF13.4
2022-04-147
PRE
The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis
2022-01-0511
OAAI